Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Kuperberg, GR
and
Murray, R
1996.
ADVANCES IN THE TREATMENT OF SCHIZOPHRENIA.
International Journal of Clinical Practice,
Vol. 50,
Issue. 6,
p.
315.
Pantelis, Christos
and
Barnes, Thomas R.E.
1996.
Drug Strategies and Treatment-Resistant Schizophrenia.
Australian & New Zealand Journal of Psychiatry,
Vol. 30,
Issue. 1,
p.
20.
Peacock, Linda
and
Gerlach, Jes
1996.
Antipsychotics.
Vol. 120,
Issue. ,
p.
359.
Glick, Ira D
Lecrubier, Yves
Montgomery, Stuart A
Vinar, Oldrich
and
Klein, Donald F
1996.
Efficacious and Safe Psychotropics Not Available in the United States.
Psychiatric Annals,
Vol. 26,
Issue. 6,
p.
354.
Boyer, P
and
Lecrubier, Y
1996.
Atypical antipsychotic drugs in dysthymia: placebo controlled studies of amisulpride versus imipramine, versus amineptine.
European Psychiatry,
Vol. 11,
Issue. S3,
p.
135s.
Langer, Salomon Z.
1997.
25 Years since the discovery of presynaptic receptors: present knowledge and future perspectives.
Trends in Pharmacological Sciences,
Vol. 18,
Issue. 3,
p.
95.
McPhillips, Mike A.
and
Barnes, Thomas R.E.
1997.
Negative symptoms.
Current Opinion in Psychiatry,
Vol. 10,
Issue. 1,
p.
30.
Waddington, John L.
Scully, Paul J.
and
O'Callaghan, Eadbhard
1997.
The new antipsychotics, and their potential for early intervention in schizophrenia.
Schizophrenia Research,
Vol. 28,
Issue. 2-3,
p.
207.
Lecrubier, Y
Boyer, P
Turjanski, S
and
Rein, W
1997.
Amisulpride versus imipramine and placebo in dysthymia and major depression.
Journal of Affective Disorders,
Vol. 43,
Issue. 2,
p.
95.
Speller, Jeremy C.
Barnes, Thomas R. E.
Curson, David A.
Pantelis, Christos
and
Alberts, J. L.
1997.
One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms.
British Journal of Psychiatry,
Vol. 171,
Issue. 6,
p.
564.
Loo, H.
Poirier-Littre, M.-F.
Theron, M.
Rein, W.
and
Fleurot, O.
1997.
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.
British Journal of Psychiatry,
Vol. 170,
Issue. 1,
p.
18.
Cudennec, Annie
Fage, Dominique
Bénavidès, Jesús
and
Scatton, Bernard
1997.
Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.
Brain Research,
Vol. 768,
Issue. 1-2,
p.
257.
Möller, H.-J.
1998.
Schizophrenie — Moderne Konzepte zu Diagnostik, Pathogenese und Therapie.
p.
207.
Puech, A.
Fleurot, O.
and
Rein, W.
1998.
Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose‐ranging study vs. haloperidol.
Acta Psychiatrica Scandinavica,
Vol. 98,
Issue. 1,
p.
65.
Laduron, Pierre M
1998.
Presynaptic receptors: more hetero than auto.
Trends in Pharmacological Sciences,
Vol. 19,
Issue. 4,
p.
127.
King, David J
1998.
Drug treatment of the negative symptoms of schizophrenia.
European Neuropsychopharmacology,
Vol. 8,
Issue. 1,
p.
33.
Marra, Donata
Warot, Dominique
Payan, Christine
Hispard, Eric
Dally, Sylvain
and
Puech, Alain Jacques
1998.
Anhedonia and relapse in alcoholism.
Psychiatry Research,
Vol. 80,
Issue. 2,
p.
187.
King, David J.
1998.
Atypical antipsychotics and the negative symptoms of schizophrenia.
Advances in Psychiatric Treatment,
Vol. 4,
Issue. 1,
p.
53.
Reid, S.
and
Turner, J.
1998.
Amisulpride in schizophrenia.
British Journal of Psychiatry,
Vol. 172,
Issue. 5,
p.
450.
Müller, N.
Froschmayr, S.
Riedel, M.
and
Möller, H.-J.
1999.
Atypische Neuroleptika.
p.
109.
eLetters
No eLetters have been published for this article.